The theme of this project is the evaluation of newly available compounds modulating brain monoamine systems as potential treatments for cocaine or methamphetamine dependence. The selected medications have not yet been evaluated in patients with stimulant dependence, so assessment of their effects in this population will provide critical new information for the addiction research field. The proposed medications for cocaine dependence are RTI-336 and JD-Tic. RTI-336 is a selective inhibitor of the dopamine transporter (DAT) that reduces cocaine self-administration by rats and monkeys. JD-Tic is a long-acting, orally active kappa opioid antagonist that blocks stress-induced reinstatement of cocaine-seeking behavior in rats. Kappa opioid receptors are up-regulated in cocaine users, indicating that kappa opioid systems may play an important role in cocaine relapse. The proposed medications for methamphetamine dependence are YPK10A and SYN-115. YPK10A, previously known as R228060, has negligible activity at monoamine transporters and receptors but has a stimulant-like behavioral profile, suggesting that it may have a novel mechanism of action. YPK10A reduces cocaine self-administration in rats, suggesting that it has potential efficacy for treating stimulant dependence. SYN-115 is a selective adenosine-2a (A2a) receptor antagonist that reduces the rewarding effects of cocaine in the rat conditioned place preference test, probably by enhancing dopaminergic neurotransmission. Consistent with this, an A2a antagonist is undergoing late phase clinical trials for the treatment of Parkinson's disease. Overall, the planned phase I studies in this project will provide critical information regarding the safety and potential efficacy of these compounds as treatments for cocaine or methamphetamine dependence. We will use this information to design outpatient trials to evaluate medications as treatments for cocaine or methamphetamine dependence. In addition, we will use the results from these trials to define the phenotypes and to develop endophenotypes that will be used in the pharmacogenetic core to identify genetic factors associated with these variables.

Public Health Relevance

Early phase research studies are needed to determine the safety and potential efficacy of new treatments for stimulant dependence. We propose four studies assessing the effects of novel medications combined with either cocaine or methamphetamine. The results we obtain will guide subsequent research aimed at identifying effective treatments for cocaine and methamphetamine dependence.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Specialized Center (P50)
Project #
5P50DA018197-10
Application #
8470148
Study Section
Special Emphasis Panel (ZDA1-SXC-E)
Project Start
Project End
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
10
Fiscal Year
2013
Total Cost
$122,762
Indirect Cost
$77,617
Name
Baylor College of Medicine
Department
Type
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Cao, Bo; Bauer, Isabelle E; Sharma, Ajaykumar N et al. (2016) Reduced hippocampus volume and memory performance in bipolar disorder patients carrying the BDNF val66met met allele. J Affect Disord 198:198-205
Shorter, Daryl; Nielsen, David A; Hamon, Sara C et al. (2016) The α-1 adrenoceptor (ADRA1A) genotype moderates the magnitude of acute cocaine-induced subjective effects in cocaine-dependent individuals. Pharmacogenet Genomics 26:428-35
Azadeh, Shabnam; Hobbs, Brian P; Ma, Liangsuo et al. (2016) Integrative Bayesian analysis of neuroimaging-genetic data with application to cocaine dependence. Neuroimage 125:813-24
Li, Xiaofan; Shorter, Daryl; Kosten, Thomas R (2016) Buprenorphine Prescribing: To Expand or Not to Expand. J Psychiatr Pract 22:183-92
Brewer 3rd, Alex J; Nielsen, David A; Spellicy, Catherine J et al. (2015) Genetic variation of the dopamine transporter (DAT1) influences the acute subjective responses to cocaine in volunteers with cocaine use disorders. Pharmacogenet Genomics 25:296-304
Shorter, Daryl; Hsieh, John; Kosten, Thomas R (2015) Pharmacologic management of comorbid post-traumatic stress disorder and addictions. Am J Addict 24:705-12
Ma, Liangsuo; Steinberg, Joel L; Cunningham, Kathryn A et al. (2015) Inhibitory behavioral control: A stochastic dynamic causal modeling study comparing cocaine dependent subjects and controls. Neuroimage Clin 7:837-47
Patriquin, Michelle A; Bauer, Isabelle E; Soares, Jair C et al. (2015) Addiction pharmacogenetics: a systematic review of the genetic variation of the dopaminergic system. Psychiatr Genet 25:181-93
Newton, Thomas F; Haile, Colin N; Mahoney 3rd, James J et al. (2015) Dopamine D3 receptor-preferring agonist enhances the subjective effects of cocaine in humans. Psychiatry Res 230:44-9
Bauer, Isabelle E; Soares, Jair C; Nielsen, David A (2015) The role of opioidergic genes in the treatment outcome of drug addiction pharmacotherapy: A systematic review. Am J Addict 24:15-23

Showing the most recent 10 out of 65 publications